AzTrials
AzTrials

Heart Failure With Preserved Ejection FractionPhase 3PARAGON-HFNCT01920711

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

A Phase 3 study testing LCZ696 and Valsartan in people with Heart Failure With Preserved Ejection Fraction, run by Novartis Pharmaceuticals at 715 sites in 43 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction. Read more about this study

Who is it for?
Ages 50 years and older
What is being tested?
LCZ696 and Valsartan
Could I receive a placebo?
No, everyone receives an active treatment
How many people
4,822 participants
Where
715 sitesin 43 countries
Study dates
18 Jul 2014to 7 Jun 2019
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Left ventricular ejection fraction (LVEF) ≥45% by echo during screening epoch or within 6 months prior to study entry.
  • Symptom(s) of heart failure (HF) and requiring treatment with diuretic(s) for HF at least 30 days prior to study entry.
  • Current symptom(s) of HF (NYHA class II-IV)
  • Structural heart disease (left atrial enlargement or left ventricular hypertrophy) documented by echocardiogram.
  • Elevated NT-proBNP

Who cannot join

  • Any prior measurement of LVEF < 40%.
  • Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months , or urgent percutaneous coronary intervention within 3 months or and elective PCI within 30 days prior to entry.
  • Any clinical event within the 6 months prior to entry could have reduced the LVEF (e.g., MI, CABG), unless an echo measurement performed after the event confirms a LVEF ≥45%.
  • Current acute decompensated HF requiring therapy.
  • Patients who require treatment with 2 or more of the following: an angiotensin converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB) or a renin inhibitor.
  • Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, hemoglobin (Hgb) <10 g/dl, or body mass index (BMI) > 40 kg/m2.
  • Systolic blood pressure (SBP) ≥ 180 mmHg at entry, or SBP >150 mmHg and <180 mmHg at entry unless the patient is receiving 3 or more antihypertensive drugs, or SBP < 110 mmHg at entry.
  • Other protocol-defined inclusion/exclusion criteria may apply.

Trial locations and contacts

715 sites in 43 countries.

715 sites in 43 countries

United States110 sites

  • Novartis Investigative Site

    Albuquerque, New Mexico, 87102

  • Novartis Investigative Site

    Ann Arbor, Michigan, 48105

  • Novartis Investigative Site

    Atlanta, Georgia, 30309

  • Novartis Investigative Site

    Atlanta, Georgia, 30310-1495

  • Novartis Investigative Site

    Baltimore, Maryland, 21229

  • Novartis Investigative Site

    Baltimore, Maryland, 21287

  • Novartis Investigative Site

    Baton Rouge, Louisiana, 70808

  • Novartis Investigative Site

    Beaumont, Texas, 77702

  • Novartis Investigative Site

    Belzoni, Mississippi, 39038

  • Novartis Investigative Site

    Beverly Hills, California, 90211

  • Novartis Investigative Site

    Biddeford, Maine, 04005

  • Novartis Investigative Site

    Boston, Massachusetts, 02118

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Bradenton, Florida, 34209

  • Novartis Investigative Site

    Brooklyn, New York, 11215

  • Novartis Investigative Site

    Buffalo, New York, 14203

  • Novartis Investigative Site

    Buffalo, New York, 14215

  • Novartis Investigative Site

    Canton, Ohio, 44710

  • Novartis Investigative Site

    Chapel Hill, North Carolina, 27599-7075

  • Novartis Investigative Site

    Charleston, South Carolina, 29403

  • Novartis Investigative Site

    Chicago, Illinois, 60611

  • Novartis Investigative Site

    Chicago, Illinois, 60637

  • Novartis Investigative Site

    Columbia, Maryland, 21044

  • Novartis Investigative Site

    Covington, Georgia, 30014

  • Novartis Investigative Site

    Cumming, Georgia, 30041

  • Novartis Investigative Site

    Dallas, Texas, 75216

  • Novartis Investigative Site

    Dallas, Texas, 75231

  • Novartis Investigative Site

    Dallas, Texas, 75235

  • Novartis Investigative Site

    Denver, Colorado, 80220

  • Novartis Investigative Site

    Detroit, Michigan, 48202

  • Novartis Investigative Site

    Evanston, Illinois, 60201

  • Novartis Investigative Site

    Flushing, New York, 11355

  • Novartis Investigative Site

    Gainesville, Florida, 32608

  • Novartis Investigative Site

    Grand Blanc, Michigan, 48439

  • Novartis Investigative Site

    Grand Forks, North Dakota, 58201

  • Novartis Investigative Site

    Hammond, Louisiana, 70403

  • Novartis Investigative Site

    Hartford, Connecticut, 06105

  • Novartis Investigative Site

    Hazel Crest, Illinois, 60429

  • Novartis Investigative Site

    Houston, Texas, 77030

  • Novartis Investigative Site

    Houston, Texas, 77094

  • Novartis Investigative Site

    Huntsville, Alabama, 35801

  • Novartis Investigative Site

    Jackson, Mississippi, 39216

  • Novartis Investigative Site

    Kalispell, Montana, 59901 3158

  • Novartis Investigative Site

    Kingston, New York, 12401

  • Novartis Investigative Site

    Knoxville, Tennessee, 37917

  • Novartis Investigative Site

    Lafayette, Louisiana, 70508

  • Novartis Investigative Site

    Lake Worth, Florida, 33461

  • Novartis Investigative Site

    Lebanon, New Hampshire, 03756

  • Novartis Investigative Site

    Lincoln, Nebraska, 68506

  • Novartis Investigative Site

    Little Rock, Arkansas, 72204

  • Novartis Investigative Site

    Livingston, Texas, 77351

  • Novartis Investigative Site

    Lombard, Illinois, 60148

  • Novartis Investigative Site

    Los Angeles, California, 90073

  • Novartis Investigative Site

    Louisville, Kentucky, 40206

  • Novartis Investigative Site

    Madison, Wisconsin, 53705

  • Novartis Investigative Site

    Madison, Wisconsin, 53792-1615

  • Novartis Investigative Site

    Marion, Ohio, 43302

  • Novartis Investigative Site

    Maywood, Illinois, 60153

  • Novartis Investigative Site

    McKinney, Texas, 75069

  • Novartis Investigative Site

    Memphis, Tennessee, 38104

  • Novartis Investigative Site

    Miami, Florida, 33143

  • Novartis Investigative Site

    Milwaukee, Wisconsin, 53215

  • Novartis Investigative Site

    Minneapolis, Minnesota, 55417

  • Novartis Investigative Site

    Minneapolis, Minnesota, 55433

  • Novartis Investigative Site

    Minneapolis, Minnesota, 55455

  • Novartis Investigative Site

    Mobile, Alabama, 36608

  • Novartis Investigative Site

    Morristown, New Jersey, 07960

  • Novartis Investigative Site

    Muscle Shoals, Alabama, 35662

  • Novartis Investigative Site

    Nashville, Tennessee, 37203

  • Novartis Investigative Site

    Nashville, Tennessee, 37212

  • Novartis Investigative Site

    New Brunswick, New Jersey, 08901

  • Novartis Investigative Site

    New Haven, Connecticut, 06520-8062

  • Novartis Investigative Site

    Northport, New York, 11768

  • Novartis Investigative Site

    Northridge, California, 91325

  • Novartis Investigative Site

    Oakbrook Terrace, Illinois, 60181

  • Novartis Investigative Site

    Orange, California, 92868

  • Novartis Investigative Site

    Peoria, Illinois, 61602

  • Novartis Investigative Site

    Philadelphia, Pennsylvania, 19107

  • Novartis Investigative Site

    Portland, Maine, 04102

  • Novartis Investigative Site

    Portland, Oregon, 97225

  • Novartis Investigative Site

    Providence, Rhode Island, 02908

  • Novartis Investigative Site

    Quincy, Illinois, 62301

  • Novartis Investigative Site

    Rapid City, South Dakota, 57701

  • Novartis Investigative Site

    Ridgewood, New Jersey, 07450

  • Novartis Investigative Site

    Rochester, New York, 14642

  • Novartis Investigative Site

    Saginaw, Michigan, 48601

  • Novartis Investigative Site

    Saint Cloud, Minnesota, 56303

  • Novartis Investigative Site

    Saint Paul, Minnesota, 55102

  • Novartis Investigative Site

    Salt Lake City, Utah, 84124

  • Novartis Investigative Site

    Salt Lake City, Utah, 84132

  • Novartis Investigative Site

    San Antonio, Texas, 78234

  • Novartis Investigative Site

    San Diego, California, 92161

  • Novartis Investigative Site

    Santa Ana, California, 92704

  • Novartis Investigative Site

    Saratoga Springs, New York, 12866

  • Novartis Investigative Site

    Seattle, Washington, 98122

  • Novartis Investigative Site

    Seattle, Washington, 98195

  • Novartis Investigative Site

    Sioux Falls, South Dakota, 57104

  • Novartis Investigative Site

    Slidell, Louisiana, 70458

  • Novartis Investigative Site

    St Louis, Missouri, 63110

  • Novartis Investigative Site

    St Louis, Missouri, 63136

  • Novartis Investigative Site

    Stamford, Connecticut, 06905

  • Novartis Investigative Site

    Tallahassee, Florida, 32308

  • Novartis Investigative Site

    The Bronx, New York, 10467

  • Novartis Investigative Site

    Tomball, Texas, 77375

  • Novartis Investigative Site

    Tulsa, Oklahoma, 74133

  • Novartis Investigative Site

    Warwick, Rhode Island, 02886

  • Novartis Investigative Site

    West Haven, Connecticut, 06516

  • Novartis Investigative Site

    White River Junction, Vermont, 05009

  • Novartis Investigative Site

    Winston-Salem, North Carolina, 27157

  • Novartis Investigative Site

    Yardley, Pennsylvania, 19067

Other trials in United States

Germany64 sites

  • Novartis Investigative Site

    Aachen, 52074

  • Novartis Investigative Site

    Bad Homburg, 61348

  • Novartis Investigative Site

    Bad Krozingen, 79189

  • Novartis Investigative Site

    Bamberg, 96049

  • Novartis Investigative Site

    Berlin, 10789

  • Novartis Investigative Site

    Berlin, 12157

  • Novartis Investigative Site

    Berlin, 12683

  • Novartis Investigative Site

    Berlin, 13086

  • Novartis Investigative Site

    Berlin, 13353

  • Novartis Investigative Site

    Berlin, 13405

  • Novartis Investigative Site

    Buch, 13125

  • Novartis Investigative Site

    Chemnitz, 09126

  • Novartis Investigative Site

    Chemnitz, 09130

  • Novartis Investigative Site

    Cologne, 51065

  • Novartis Investigative Site

    Dessau, 06846

  • Novartis Investigative Site

    Dresden, Saxony, 01099

  • Novartis Investigative Site

    Dresden, 01277

  • Novartis Investigative Site

    Dresden, 01307

  • Novartis Investigative Site

    Dresden, 01309

  • Novartis Investigative Site

    Duisburg, 47137

  • Novartis Investigative Site

    Eilenburg, D 04838

  • Novartis Investigative Site

    Elsterwerda, 04910

  • Novartis Investigative Site

    Essen, 45355

  • Novartis Investigative Site

    Frankfurt, 60594

  • Novartis Investigative Site

    Frankfurt, 65929

  • Novartis Investigative Site

    Hamburg, 20099

  • Novartis Investigative Site

    Hamburg, 20246

  • Novartis Investigative Site

    Hamburg, 22041

  • Novartis Investigative Site

    Hamburg, 22765

  • Novartis Investigative Site

    Haßloch, 67454

  • Novartis Investigative Site

    Heidenau, 01809

  • Novartis Investigative Site

    Heppenheim an der Bergstrasse, 64646

  • Novartis Investigative Site

    Homburg, 66421

  • Novartis Investigative Site

    Ingelheim, 55218

  • Novartis Investigative Site

    Jena, 07740

  • Novartis Investigative Site

    Kassel, 34121

  • Novartis Investigative Site

    Kleve, 47533

  • Novartis Investigative Site

    Koblenz, 56068

  • Novartis Investigative Site

    Leipzig, 04103

  • Novartis Investigative Site

    Löhne, 32584

  • Novartis Investigative Site

    Ludwigshafen, 67071

  • Novartis Investigative Site

    Lüneburg, 21339

  • Novartis Investigative Site

    Mainz, 55116

  • Novartis Investigative Site

    Meißen, 01662

  • Novartis Investigative Site

    Memmingen, 87700

  • Novartis Investigative Site

    Muehldorf Am Inn, 84453

  • Novartis Investigative Site

    Mühldorf, 84453

  • Novartis Investigative Site

    München, 81675

  • Novartis Investigative Site

    Munich, 80638

  • Novartis Investigative Site

    Münster, 48149

  • Novartis Investigative Site

    Nienburg, 31582

  • Novartis Investigative Site

    Northeim, 37154

  • Novartis Investigative Site

    Oschatz, 04758

  • Novartis Investigative Site

    Papenburg, 26871

  • Novartis Investigative Site

    Reinfeld, 23858

  • Novartis Investigative Site

    Riesa, 01589

  • Novartis Investigative Site

    Rodgau, 63110

  • Novartis Investigative Site

    Siegen, 57072

  • Novartis Investigative Site

    Ulm, 89077

  • Novartis Investigative Site

    Wermsdorf, 04779

  • Novartis Investigative Site

    Weyhe, 28844

  • Novartis Investigative Site

    Witten, 58455

  • Novartis Investigative Site

    Wittenberg, 06886

  • Novartis Investigative Site

    Würzburg, 97080

Other trials in Germany

China39 sites

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100037

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100039

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100044

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100730

  • Novartis Investigative Site

    Beijing, 100029

  • Novartis Investigative Site

    Beijing, 100034

  • Novartis Investigative Site

    Changchun, Jilin, 130022

  • Novartis Investigative Site

    Changsha, Hunan, 410003

  • Novartis Investigative Site

    Chengdu, Sichuan, 610041

  • Novartis Investigative Site

    Chongqing, Chongqing Municipality, 400010

  • Novartis Investigative Site

    Chongqing, 400037

  • Novartis Investigative Site

    Guangzhou, Guangdong, 51000

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510080

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510515

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310009

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310013

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310016

  • Novartis Investigative Site

    Jilin City, Jilin, 132000

  • Novartis Investigative Site

    Jinan, 250012

  • Novartis Investigative Site

    Lanzhou, Gansu, 730030

  • Novartis Investigative Site

    Nanchang, Jiangxi, 330006

  • Novartis Investigative Site

    Nanjing, Jiangsu, 210009

  • Novartis Investigative Site

    Nanjing, Jiangsu, 210029

  • Novartis Investigative Site

    Nanjing, 210036

  • Novartis Investigative Site

    Nanning, Guangxi, 530021

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality, 200032

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality, 200120

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality

  • Novartis Investigative Site

    Shanghai, 200025

  • Novartis Investigative Site

    Shanghai, 200031

  • Novartis Investigative Site

    Shanghai, 200080

  • Novartis Investigative Site

    Shenyang, Liaoning, 110003

  • Novartis Investigative Site

    Shenyang, Liaoning, 110016

  • Novartis Investigative Site

    Suzhou, Jiangsu, 215004

  • Novartis Investigative Site

    Tianjin, Tianjin Municipality, 300121

  • Novartis Investigative Site

    Ürümqi, Xinjiang, 830054

  • Novartis Investigative Site

    Wuxi, Jiangsu

  • Novartis Investigative Site

    Xi’an, Shanxi, 710032

  • Novartis Investigative Site

    Xian, Shanxi, 710061

Other trials in China

Spain31 sites

  • Novartis Investigative Site

    A Coruña, Galicia, 15006

  • Novartis Investigative Site

    Almería, Andalusia, 04120

  • Novartis Investigative Site

    Alzira, Valencia, 46600

  • Novartis Investigative Site

    Aranda de Duero, Castille and León, 09400

  • Novartis Investigative Site

    Badalona, Catalonia, 08916

  • Novartis Investigative Site

    Barcelona, Catalonia, 08003

  • Novartis Investigative Site

    Ciudad Real, 13005

  • Novartis Investigative Site

    Córdoba, Andalusia, 14004

  • Novartis Investigative Site

    El Palmar, Murcia, 30120

  • Novartis Investigative Site

    León, Castille and León, 24071

  • Novartis Investigative Site

    Lleida, Catalonia, 25198

  • Novartis Investigative Site

    Madrid, 28009

  • Novartis Investigative Site

    Madrid, 28034

  • Novartis Investigative Site

    Madrid, 28040

  • Novartis Investigative Site

    Madrid, 28046

  • Novartis Investigative Site

    Madrid, 28222

  • Novartis Investigative Site

    Málaga, Andalusia, 29010

  • Novartis Investigative Site

    Marbella, Andalusia, 29600

  • Novartis Investigative Site

    Mérida, Extremadura, 06800

  • Novartis Investigative Site

    Móstoles, Madrid, 28935

  • Novartis Investigative Site

    Olot, Girona, 17800

  • Novartis Investigative Site

    Sanlúcar de Barrameda, Andalusia, 11540

  • Novartis Investigative Site

    Sant Joan Despí, Barcelona, 08970

  • Novartis Investigative Site

    Santander, Cantabria, 39008

  • Novartis Investigative Site

    Santiago de Compostela, Galicia, 15706

  • Novartis Investigative Site

    Seville, Andalusia, 41013

  • Novartis Investigative Site

    Seville, Andalusia, 41014

  • Novartis Investigative Site

    Valencia, Valencia, 46010

  • Novartis Investigative Site

    Valencia, Valencia, 46014

  • Novartis Investigative Site

    Valencia, Valencia, 46026

  • Novartis Investigative Site

    Villamartín, Cadiz, 11650

Other trials in Spain

United Kingdom30 sites

  • Novartis Investigative Site

    Basingstoke, Hampshire, RG24 9NA

  • Novartis Investigative Site

    Cheshire, CW1 4QJ

  • Novartis Investigative Site

    Clydebank, West Dumbartonshire, G81 4HX

  • Novartis Investigative Site

    Coventry, CV2 2DX

  • Novartis Investigative Site

    Darlington, Co Durham, DL3 8SQ

  • Novartis Investigative Site

    Dorchester, Dorset, DT1 2JY

  • Novartis Investigative Site

    Dundee, DD1 9SY

  • Novartis Investigative Site

    Durham, County Durham, DH1 5TW

  • Novartis Investigative Site

    Gateshead, Tyne and Wear, NE9 6SX

  • Novartis Investigative Site

    Glasgow, Scotland, G12 8TA

  • Novartis Investigative Site

    Glasgow, G20 0XA

  • Novartis Investigative Site

    Harrow, Middlesex, HA1 3UJ

  • Novartis Investigative Site

    High Wycombe, Buckinghamshire, HP11 2TT

  • Novartis Investigative Site

    Hull, HU16 5JQ

  • Novartis Investigative Site

    London, SE5 9RS

  • Novartis Investigative Site

    London, SW 6NP

  • Novartis Investigative Site

    Newport, NP20 2UB

  • Novartis Investigative Site

    Nottingham, NG5 1PB

  • Novartis Investigative Site

    Oldham, Lancashire, OL1 2JH

  • Novartis Investigative Site

    Peterborough, GBR, PE3 6DA

  • Novartis Investigative Site

    Portadown, Nothern Ireland, BT63 5QQ

  • Novartis Investigative Site

    Portsmouth, Hampshire, PO6 3LY

  • Novartis Investigative Site

    Sheffield, S5 7AU

  • Novartis Investigative Site

    Stockton-on-Tees, Cleveland, TS19 8PE

  • Novartis Investigative Site

    Swindon, SN3 6BB

  • Novartis Investigative Site

    Taunton, Somerset, TA1 5DA

  • Novartis Investigative Site

    Torquay, Devon, TQ2 7AA

  • Novartis Investigative Site

    Wansford, Peterborough, PE8 6PL

  • Novartis Investigative Site

    Wiltshire, SN15 2SB

  • Novartis Investigative Site

    Wrexham, LL13 7TD

Other trials in United Kingdom

Russia29 sites

  • Novartis Investigative Site

    Ivanovo, 153012

  • Novartis Investigative Site

    Izhevsk, 426009

  • Novartis Investigative Site

    Izhevsk, 426063

  • Novartis Investigative Site

    Kemerovo, 650029

  • Novartis Investigative Site

    Kemerovo, 650099

  • Novartis Investigative Site

    Kirov, 610027

  • Novartis Investigative Site

    Kirov, 610035

  • Novartis Investigative Site

    Moscow, 101990

  • Novartis Investigative Site

    Moscow, 117198

  • Novartis Investigative Site

    Moscow, 121309

  • Novartis Investigative Site

    Moscow, 121552

  • Novartis Investigative Site

    N.Novgorod, 603005

  • Novartis Investigative Site

    Perm, 614990

  • Novartis Investigative Site

    Rostov-on-Don, 344022

  • Novartis Investigative Site

    Rostov-on-Don, 344068

  • Novartis Investigative Site

    Saint Petersburg, 192257

  • Novartis Investigative Site

    Saint Petersburg, 194044

  • Novartis Investigative Site

    Saint Petersburg, 194295

  • Novartis Investigative Site

    Saint Petersburg, 196601

  • Novartis Investigative Site

    Saint Petersburg, 197022

  • Novartis Investigative Site

    Saint Petersburg, 197110

  • Novartis Investigative Site

    Saint Petersburg, 197341

  • Novartis Investigative Site

    Saint Petersburg, 199106

  • Novartis Investigative Site

    Saratov, 410012

  • Novartis Investigative Site

    Sestroretsk, 197706

  • Novartis Investigative Site

    Smolensk, 214018

  • Novartis Investigative Site

    Yaroslavl, 150003

  • Novartis Investigative Site

    Yekaterinburg, 620028

  • Novartis Investigative Site

    Yekaterinburg, 620137

Other trials in Russia

Italy28 sites

  • Novartis Investigative Site

    Aosta, AO, 11100

  • Novartis Investigative Site

    Ariccia, RM, 00041

  • Novartis Investigative Site

    Bergamo, BG, 24127

  • Novartis Investigative Site

    Bologna, BO, 40138

  • Novartis Investigative Site

    Brescia, BS, 25123

  • Novartis Investigative Site

    Cona, FE, 44100

  • Novartis Investigative Site

    Cortona, AR, 52044

  • Novartis Investigative Site

    Messina, ME, 98125

  • Novartis Investigative Site

    Milan, MI, 20162

  • Novartis Investigative Site

    Milan, 20149

  • Novartis Investigative Site

    Monza, MB, 20900

  • Novartis Investigative Site

    Naples, 80131

  • Novartis Investigative Site

    Padova, PD, 35128

  • Novartis Investigative Site

    Palmanova, UD, 33057

  • Novartis Investigative Site

    Pavia, PV, 27100

  • Novartis Investigative Site

    Perugia, PG, 06100

  • Novartis Investigative Site

    Perugia, PG, 06129

  • Novartis Investigative Site

    Pozzilli, IS, 86077

  • Novartis Investigative Site

    Roma, RM, 00163

  • Novartis Investigative Site

    Roma, RM, 00189

  • Novartis Investigative Site

    San Daniele del Friuli, UD, 33038

  • Novartis Investigative Site

    Saronno, Va, 21047

  • Novartis Investigative Site

    Sassari, SS, 07100

  • Novartis Investigative Site

    Treviglio, BG, 24047

  • Novartis Investigative Site

    Trieste, TS, 34142

  • Novartis Investigative Site

    Trieste, TS, 34149

  • Novartis Investigative Site

    Venezia, VE, 30174

  • Novartis Investigative Site

    Vimercate, MI, 200059

Other trials in Italy

Slovakia26 sites

  • Novartis Investigative Site

    Bardejov, 085 01

  • Novartis Investigative Site

    Bratislava, 821 07

  • Novartis Investigative Site

    Bratislava, 831 01

  • Novartis Investigative Site

    Bratislava, 833 48

  • Novartis Investigative Site

    Bratislava, 841 07

  • Novartis Investigative Site

    Bratislava, 842 31

  • Novartis Investigative Site

    Bratislava, 851 01

  • Novartis Investigative Site

    Brezno, Slovak Republic, 977 42

  • Novartis Investigative Site

    Komárno, Slovak Republic, 94501

  • Novartis Investigative Site

    Košice, 040 01

  • Novartis Investigative Site

    Levice, Slovak Republic, 93401

  • Novartis Investigative Site

    Levice, 934 01

  • Novartis Investigative Site

    Lučenec, 984 01

  • Novartis Investigative Site

    Lučenec, 98439

  • Novartis Investigative Site

    Námestovo, Slovak Republic, 02901

  • Novartis Investigative Site

    Nitra, 949 01

  • Novartis Investigative Site

    Nitra, 949 88

  • Novartis Investigative Site

    Nové Zámky, 940 01

  • Novartis Investigative Site

    Nové Zámky, 94002

  • Novartis Investigative Site

    Piešťany, 921 01

  • Novartis Investigative Site

    Považská Bystrica, Slovak Republic, 01701

  • Novartis Investigative Site

    Prešov, Slovak Republic, 08001

  • Novartis Investigative Site

    Prešov, 080 01

  • Novartis Investigative Site

    Svidník, 089 01

  • Novartis Investigative Site

    Trebišov, 075 01

  • Novartis Investigative Site

    Žilina, 012 07

Other trials in Slovakia

Argentina25 sites

  • Novartis Investigative Site

    Buenos Aires, C1425AGP

  • Novartis Investigative Site

    Buenos Aires, C1428DCO

  • Novartis Investigative Site

    Caba, Buenos Aires, C1280AEB

  • Novartis Investigative Site

    CABA, Buenos Aires, 1407

  • Novartis Investigative Site

    CABA, Buenos Aires, C1056ABJ

  • Novartis Investigative Site

    CABA, Buenos Aires F.D., C1179AAB

  • Novartis Investigative Site

    CABA, C1119ACN

  • Novartis Investigative Site

    Córdoba, X5000AAX

  • Novartis Investigative Site

    Córdoba, X5000EVQ

  • Novartis Investigative Site

    Córdoba, X5009BSN

  • Novartis Investigative Site

    Córdoba, X5016KET

  • Novartis Investigative Site

    Córdoba, X5022CPU

  • Novartis Investigative Site

    Formosa, P3600

  • Novartis Investigative Site

    Posadas, Misiones Province, N3300AHX

  • Novartis Investigative Site

    Quilmes, Buenos Aires, B1878GEG

  • Novartis Investigative Site

    Ramos Mejía, Buenos Aires, B1704ETD

  • Novartis Investigative Site

    Rosario, Santa Fe Province, 2000

  • Novartis Investigative Site

    Rosario, Santa Fe Province, 3080

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000DSV

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000QID

  • Novartis Investigative Site

    Salta, Salta Province, A4406BPF

  • Novartis Investigative Site

    San Luis, D5702JRS

  • Novartis Investigative Site

    San Miguel de Tucumán, San Miguel de Tucuman, T4000ICL

  • Novartis Investigative Site

    San Miguel de Tucumán, Tucumán Province, T4000IFL

  • Novartis Investigative Site

    Santa Fe, S3000FWO

Other trials in Argentina

Czechia21 sites

  • Novartis Investigative Site

    Brandýs nad Labem, Czech Republic, 250 01

  • Novartis Investigative Site

    Brno, Czech Republic, 60200

  • Novartis Investigative Site

    CZE, 11000

  • Novartis Investigative Site

    Ivančice, Czech Republic, 66491

  • Novartis Investigative Site

    Kladno, Czech Republic, 272 80

  • Novartis Investigative Site

    Kolín, 280 20

  • Novartis Investigative Site

    Liberec, Czech Republic, 460 05

  • Novartis Investigative Site

    Louny, Czech Republic

  • Novartis Investigative Site

    Mariánské Lázně, 353 01

  • Novartis Investigative Site

    Ostrava, Czech Republic, 70200

  • Novartis Investigative Site

    Pilsen, Czech Republic, 30100

  • Novartis Investigative Site

    Policska, CZE, 57201

  • Novartis Investigative Site

    Prague, Czech Republic, 140 21

  • Novartis Investigative Site

    Prague, CZE, 128 08

  • Novartis Investigative Site

    Rožnov pod Radhoštěm, Czech Republic, 756 61

  • Novartis Investigative Site

    Svitavy, Czech Republic, 568 25

  • Novartis Investigative Site

    Třebíč, Czech Republic, 674 01

  • Novartis Investigative Site

    Uherské Hradiště, 68601

  • Novartis Investigative Site

    Ústí nad Labem, Czech Republic, 400 01

  • Novartis Investigative Site

    Ústí nad Labem, CZE, 400 01

  • Novartis Investigative Site

    Znojmo, Czech Republic, 66902

Other trials in Czechia

Bulgaria19 sites

  • Novartis Investigative Site

    Burgas, 8127

  • Novartis Investigative Site

    Pazardzhik, 4400

  • Novartis Investigative Site

    Pleven, 5800

  • Novartis Investigative Site

    Plovdiv, 4000

  • Novartis Investigative Site

    Plovdiv, 4002

  • Novartis Investigative Site

    Shumen, 9700

  • Novartis Investigative Site

    Silistra, 7500

  • Novartis Investigative Site

    Sliven, 8800

  • Novartis Investigative Site

    Smolyan, Bulgaria, 4700

  • Novartis Investigative Site

    Sofia, 1000

  • Novartis Investigative Site

    Sofia, 1202

  • Novartis Investigative Site

    Sofia, 1233

  • Novartis Investigative Site

    Sofia, 1309

  • Novartis Investigative Site

    Sofia, 1407

  • Novartis Investigative Site

    Sofia, 1527

  • Novartis Investigative Site

    Sofia, 1606

  • Novartis Investigative Site

    Sofia, 1784

  • Novartis Investigative Site

    Varna, 9010

  • Novartis Investigative Site

    Veliko Tarnovo, 5000

Other trials in Bulgaria

Japan19 sites

  • Novartis Investigative Site

    Amagasaki, Hyōgo, 660 8550

  • Novartis Investigative Site

    Chikushino-shi, Fukuka, 818-8516

  • Novartis Investigative Site

    Chiyoda-ku, Tokyo, 101-8309

  • Novartis Investigative Site

    Hachiōji, Tokyo, 192-0918

  • Novartis Investigative Site

    Kan’onjichō, Kagawa-ken, 769-1695

  • Novartis Investigative Site

    Kanazawa, Ishikawa-ken, 920 8650

  • Novartis Investigative Site

    Kashihara, Nara, 634 8522

  • Novartis Investigative Site

    Kusatsu, Shiga, 525 8585

  • Novartis Investigative Site

    Maebashi, Gunma, 371 8511

  • Novartis Investigative Site

    Morioka, Iwate, 020 0066

  • Novartis Investigative Site

    Ōgaki, Gifu, 503-8502

  • Novartis Investigative Site

    Sayama, Saitama, 350-1305

  • Novartis Investigative Site

    Sendai, Miyagi, 980 8574

  • Novartis Investigative Site

    Seto, Aichi-ken, 489-8642

  • Novartis Investigative Site

    Shinagawa-ku, Tokyo, 142-8666

  • Novartis Investigative Site

    tabashi City, Tokyo, 173-8610

  • Novartis Investigative Site

    Takamatsu, Kagawa-ken, 760 8557

  • Novartis Investigative Site

    Yokohama, Kanagawa, 227-8501

  • Novartis Investigative Site

    Yokohama, Kanagawa, 236 0051

Other trials in Japan

Canada18 sites

  • Novartis Investigative Site

    Calgary, Alberta, T2N 4Z6

  • Novartis Investigative Site

    Cambridge, Ontario, N1R 6V6

  • Novartis Investigative Site

    Halifax, Nova Scotia, B3H 2Y9

  • Novartis Investigative Site

    Hamilton, Ontario, L8L 2X2

  • Novartis Investigative Site

    Montreal, Quebec, H1T 1C8

  • Novartis Investigative Site

    Montreal, Quebec, H3G 1A4

  • Novartis Investigative Site

    Montreal, Quebec, H3T 1E2

  • Novartis Investigative Site

    Ottawa, Ontario, K1Y 4W7

  • Novartis Investigative Site

    Sainte-Foy, Quebec, G1V 4G5

  • Novartis Investigative Site

    Sherbrooke, Quebec, J1G 2E8

  • Novartis Investigative Site

    St. John's, Newfoundland and Labrador, A1B 3V6

  • Novartis Investigative Site

    Thetford-Mines, Quebec, G6G 2V4

  • Novartis Investigative Site

    Toronto, Ontario, M5B 1W8

  • Novartis Investigative Site

    Toronto, Ontario, M5G 1X5

  • Novartis Investigative Site

    Toronto, Ontario, M5S 1B2

  • Novartis Investigative Site

    Trois-Rivières, Quebec, G8Z 3R9

  • Novartis Investigative Site

    Victoria, British Columbia, V8R4R2

  • Novartis Investigative Site

    Weston, Ontario, M9N 1W4

Other trials in Canada

India16 sites

  • Novartis Investigative Site

    Ahmedabad, Gujarat, 380054

  • Novartis Investigative Site

    Bikaner, Rajasthan, 334003

  • Novartis Investigative Site

    Chandīgarh, Haryana, 160 030

  • Novartis Investigative Site

    Chennai, Tamil Nadu, 600037

  • Novartis Investigative Site

    Chennai, Tamil Nadu, 600081

  • Novartis Investigative Site

    Guntur, Andhra Pradesh, 522001

  • Novartis Investigative Site

    Gurgaon, Haryana, 122001

  • Novartis Investigative Site

    Kochi, Kerala, 683 594

  • Novartis Investigative Site

    Kolkata, West Bengal, 700 020

  • Novartis Investigative Site

    Ludhiana, Punjab, 141002

  • Novartis Investigative Site

    Madurai, Tamil Nadu, 625107

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110 060

  • Novartis Investigative Site

    New Delhi, 110025

  • Novartis Investigative Site

    Pune, Maharashtra, 411 030

  • Novartis Investigative Site

    Surat, Gujarat, 395 002

  • Novartis Investigative Site

    Visakhapatnam, Andhra Pradesh, 532 002

Other trials in India

Poland16 sites

  • Novartis Investigative Site

    Gdynia, 81-157

  • Novartis Investigative Site

    Gdynia, 81-548

  • Novartis Investigative Site

    Grodzisk Mazowiecki, 05 825

  • Novartis Investigative Site

    Katowice, 40-645

  • Novartis Investigative Site

    Krakow, 30-015

  • Novartis Investigative Site

    Krakow, 31 501

  • Novartis Investigative Site

    Lodz, Łódź Voivodeship, 90 549

  • Novartis Investigative Site

    Lublin, 20-363

  • Novartis Investigative Site

    Sandomierz, 27 600

  • Novartis Investigative Site

    Staszów, 28-200

  • Novartis Investigative Site

    Torun, 87-100

  • Novartis Investigative Site

    Warsaw, 02-097

  • Novartis Investigative Site

    Warsaw, 04-154

  • Novartis Investigative Site

    Warszawa/Anin, 04-761

  • Novartis Investigative Site

    Zabrze, 41 800

  • Novartis Investigative Site

    Zamość, 22-400

Other trials in Poland

Netherlands15 sites

  • Novartis Investigative Site

    Almelo, PP, 7609

  • Novartis Investigative Site

    Apeldoorn, DZ, 7334

  • Novartis Investigative Site

    Arnhem, 6815 AD

  • Novartis Investigative Site

    Blaricum, 1261 AN

  • Novartis Investigative Site

    Ede, 6716 RP

  • Novartis Investigative Site

    Gouda, 2803 HH

  • Novartis Investigative Site

    Groningen, 9713 GZ

  • Novartis Investigative Site

    Hardenberg, 7770 AA

  • Novartis Investigative Site

    Harderwijk, 3840 AC

  • Novartis Investigative Site

    Nijmegen, 6500 HB

  • Novartis Investigative Site

    Rotterdam, 3015 CE

  • Novartis Investigative Site

    Sneek, 8601 ZK

  • Novartis Investigative Site

    The Hague, NL, 2597 AX

  • Novartis Investigative Site

    The Hague, 2512 VA

  • Novartis Investigative Site

    Tilburg, 5022 GC

Other trials in Netherlands

Brazil14 sites

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, 30150-221

  • Novartis Investigative Site

    Blumenau, Santa Catarina, 89020 430

  • Novartis Investigative Site

    Campina Grande do Sul, Paraná, 83430-000

  • Novartis Investigative Site

    Campinas, São Paulo, 13020-431

  • Novartis Investigative Site

    Campinas, São Paulo, 13060-904

  • Novartis Investigative Site

    Curitiba, Paraná, 80730 150

  • Novartis Investigative Site

    Goiânia, Goiás, 74605-020

  • Novartis Investigative Site

    Liberdade, São Paulo, 01504-001

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90035-003

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90880-480

  • Novartis Investigative Site

    Ribeirão Preto, São Paulo, 14055-370

  • Novartis Investigative Site

    São José do Rio Preto, São Paulo, 15090 000

  • Novartis Investigative Site

    São Paulo, São Paulo, 08270-070

  • Novartis Investigative Site

    Uberlândia, Minas Gerais, 38411 186

Other trials in Brazil

France14 sites

  • Novartis Investigative Site

    Bayonne, Bayonne Cedex, 64109

  • Novartis Investigative Site

    Besançon, 25030

  • Novartis Investigative Site

    Béziers, 34525

  • Novartis Investigative Site

    Bordeaux, 33075

  • Novartis Investigative Site

    Grenoble, 38043

  • Novartis Investigative Site

    Lyon, F-69001

  • Novartis Investigative Site

    Montpellier, Herault, 34059

  • Novartis Investigative Site

    Paris, 75010

  • Novartis Investigative Site

    Poitiers, 86000

  • Novartis Investigative Site

    Pontoise, F-95300

  • Novartis Investigative Site

    Rennes, 35033

  • Novartis Investigative Site

    Toulouse, 31059

  • Novartis Investigative Site

    Tourcoing, 59208

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, 54511

Other trials in France

Hungary14 sites

  • Novartis Investigative Site

    Budapest, 1042

  • Novartis Investigative Site

    Budapest, 1085

  • Novartis Investigative Site

    Budapest, 1134

  • Novartis Investigative Site

    Budapest, 1145

  • Novartis Investigative Site

    Budapest, H 1096

  • Novartis Investigative Site

    Cegléd, 2700

  • Novartis Investigative Site

    Kistarcsa, 2143

  • Novartis Investigative Site

    Makó, 6900

  • Novartis Investigative Site

    Nyiregyháza, 4400

  • Novartis Investigative Site

    Pécs, 7623

  • Novartis Investigative Site

    Pécs, 7635

  • Novartis Investigative Site

    Szeged, H 6725

  • Novartis Investigative Site

    Székesfehérvár, H-8000

  • Novartis Investigative Site

    Zalaegerszeg, Zala County, 8900

Other trials in Hungary

Romania13 sites

  • Novartis Investigative Site

    Arad, 310158

  • Novartis Investigative Site

    Baia Mare, 430222

  • Novartis Investigative Site

    Bucharest, District 1, 014461

  • Novartis Investigative Site

    Bucharest, 050098

  • Novartis Investigative Site

    Bucharest, 062272

  • Novartis Investigative Site

    Craiova, Jud. Dolj, 200497

  • Novartis Investigative Site

    Piteşti, Argeş, 110438

  • Novartis Investigative Site

    Sibiu, Jud. Iasi, 550371

  • Novartis Investigative Site

    Târgu Mureş, 540142

  • Novartis Investigative Site

    Târgu Mureş, 540143

  • Novartis Investigative Site

    Timișoara, Timiș County, 300125

  • Novartis Investigative Site

    Timișoara, Timiș County, 300362

  • Novartis Investigative Site

    Timișoara, 300041

Other trials in Romania

Belgium12 sites

  • Novartis Investigative Site

    Aalst, 9300

  • Novartis Investigative Site

    Antwerp, 2060

  • Novartis Investigative Site

    Brasschaat, 2930

  • Novartis Investigative Site

    Brussels, 1200

  • Novartis Investigative Site

    De Pinte, 9840

  • Novartis Investigative Site

    Genk, 3600

  • Novartis Investigative Site

    Ghent, 9000

  • Novartis Investigative Site

    Hasselt, 3500

  • Novartis Investigative Site

    Huy, 4500

  • Novartis Investigative Site

    Kortrijk, 8500

  • Novartis Investigative Site

    Leuven, 3000

  • Novartis Investigative Site

    Ottignies, 1340

Other trials in Belgium

South Africa12 sites

  • Novartis Investigative Site

    Alberton, 1449

  • Novartis Investigative Site

    Bloemfontein, Free State, 9301

  • Novartis Investigative Site

    Bloemfontein, 9301

  • Novartis Investigative Site

    Cape Town, 7500

  • Novartis Investigative Site

    Cape Town, 7531

  • Novartis Investigative Site

    Cape Town, 7925

  • Novartis Investigative Site

    Durban, KwaZulu-Natal, 4052

  • Novartis Investigative Site

    Durban, 4001

  • Novartis Investigative Site

    Soweto, Gauteng, 2013

  • Novartis Investigative Site

    Tongaat, 3300

  • Novartis Investigative Site

    Western Cape, 7130

  • Novartis Investigative Site

    Worcester, 6850

Other trials in South Africa

South Korea12 sites

  • Novartis Investigative Site

    Bundang Gu, Gyeonggi-do, 13620

  • Novartis Investigative Site

    Cheongju-si, North Chungcheong, 28644

  • Novartis Investigative Site

    Daegu, 705 718

  • Novartis Investigative Site

    Gyeonggi-do, Bucheon Si, 422-711

  • Novartis Investigative Site

    Incheon, KOR, 22332

  • Novartis Investigative Site

    Seoul, Korea, 05505

  • Novartis Investigative Site

    Seoul, KOR, 08308

  • Novartis Investigative Site

    Seoul, 02841

  • Novartis Investigative Site

    Seoul, 03080

  • Novartis Investigative Site

    Seoul, 03722

  • Novartis Investigative Site

    Seoul, 06351

  • Novartis Investigative Site

    Wŏnju, Gangwon-do, 26427

Other trials in South Korea

Israel10 sites

  • Novartis Investigative Site

    Hadera, 38100

  • Novartis Investigative Site

    Hadera

  • Novartis Investigative Site

    Haifa, 3339419

  • Novartis Investigative Site

    Haifa, 3525408

  • Novartis Investigative Site

    Lower Galilee, Israel, 15208

  • Novartis Investigative Site

    Nahariya, 22100

  • Novartis Investigative Site

    Petah Tikva, 49100

  • Novartis Investigative Site

    Ramat Gan, 52621

  • Novartis Investigative Site

    Rehovot, 76100

  • Novartis Investigative Site

    Tel Giborim, Holon, 58100

Other trials in Israel

Mexico10 sites

  • Novartis Investigative Site

    Aguascalientes, 20230

  • Novartis Investigative Site

    Culiacán, Sinaloa, 80230

  • Novartis Investigative Site

    León, Guanajuato, 37530

  • Novartis Investigative Site

    Mexico City, Mexico City, 14080

  • Novartis Investigative Site

    Querétaro, 76000

  • Novartis Investigative Site

    San Juan del Río, Querétaro, 76800

  • Novartis Investigative Site

    San Luis Potosí City, San Luis Potosí, 78240

  • Novartis Investigative Site

    San Luis Potosí City, 78200

  • Novartis Investigative Site

    Torreón, Coahulia, 27000

  • Novartis Investigative Site

    Zapopan, Jalisco, 45200

Other trials in Mexico

Taiwan9 sites

  • Novartis Investigative Site

    Changhua, 50006

  • Novartis Investigative Site

    Kaohsiung City, 80756

  • Novartis Investigative Site

    New Taipei City, 22060

  • Novartis Investigative Site

    Taichung, 40447

  • Novartis Investigative Site

    Tainan, Taiwan ROC, 70403

  • Novartis Investigative Site

    Tainan, 71004

  • Novartis Investigative Site

    Taipei, 10002

  • Novartis Investigative Site

    Taipei, 11217

  • Novartis Investigative Site

    Yilan, 26058

Other trials in Taiwan

Austria8 sites

  • Novartis Investigative Site

    Braunau am Inn, A5280

  • Novartis Investigative Site

    Graz, 8020

  • Novartis Investigative Site

    Graz, A-8036

  • Novartis Investigative Site

    Grossgmain, 5084

  • Novartis Investigative Site

    Innsbruck, Tyrol, 6020

  • Novartis Investigative Site

    Linz, 4010

  • Novartis Investigative Site

    Vienna, 1130

  • Novartis Investigative Site

    Vienna, A 1090

Other trials in Austria

Greece8 sites

  • Novartis Investigative Site

    Athens, Attica, 15562

  • Novartis Investigative Site

    Athens, GR, 14233

  • Novartis Investigative Site

    Athens, 115 27

  • Novartis Investigative Site

    Athens, 12462

  • Novartis Investigative Site

    Ioannina, GR, 455 00

  • Novartis Investigative Site

    Larissa, GR, 411 10

  • Novartis Investigative Site

    Thessaloniki, 54642

  • Novartis Investigative Site

    Thessaloniki, GR 54636

Other trials in Greece

Sweden8 sites

  • Novartis Investigative Site

    Danderyd, 182 88

  • Novartis Investigative Site

    Falun, 791 82

  • Novartis Investigative Site

    Gothenburg, 413 45

  • Novartis Investigative Site

    Karlstad, 652 30

  • Novartis Investigative Site

    Lund, 222 21

  • Novartis Investigative Site

    Örebro, 701 85

  • Novartis Investigative Site

    Stockholm, 17176

  • Novartis Investigative Site

    Västerås, 72189

Other trials in Sweden

Turkey (Türkiye)8 sites

  • Novartis Investigative Site

    Haydarpasa Istanbul, 34668

  • Novartis Investigative Site

    Istanbul, TUR, 34098

  • Novartis Investigative Site

    Istanbul, 34304

  • Novartis Investigative Site

    Izmir, 35040

  • Novartis Investigative Site

    Izmir, 35340

  • Novartis Investigative Site

    Kocaeli, 41380

  • Novartis Investigative Site

    Pendik / Istanbul, Turkey, 34899

  • Novartis Investigative Site

    Sivas, 58140

Other trials in Turkey (Türkiye)

Denmark7 sites

  • Novartis Investigative Site

    Esbjerg, DK-6700

  • Novartis Investigative Site

    Glostrup Municipality, 2600

  • Novartis Investigative Site

    Herlev, 2730

  • Novartis Investigative Site

    Hvidovre, 2650

  • Novartis Investigative Site

    Randers, 8930

  • Novartis Investigative Site

    Svendborg, 5700

  • Novartis Investigative Site

    Viborg, DK-8800

Other trials in Denmark

Australia5 sites

  • Novartis Investigative Site

    Bedford Park, South Australia, 5041

  • Novartis Investigative Site

    Bundoora, Victoria, 3083

  • Novartis Investigative Site

    Epping, Victoria, 3076

  • Novartis Investigative Site

    Geelong, Victoria, 3220

  • Novartis Investigative Site

    Southport, Queensland, 4215

Other trials in Australia

Colombia5 sites

  • Novartis Investigative Site

    Barranquilla, Atlántico

  • Novartis Investigative Site

    Barranquilla, 080020

  • Novartis Investigative Site

    Barranquilla

  • Novartis Investigative Site

    Florida Blanca

  • Novartis Investigative Site

    Medellín, Antioquia, 050036

Other trials in Colombia

Peru5 sites

  • Novartis Investigative Site

    Bellavista, Lima region, CALLAO 02

  • Novartis Investigative Site

    Jesus Maria, Lima region, 11

  • Novartis Investigative Site

    Lima Cercado, Lima region, 01

  • Novartis Investigative Site

    Miraflores, Lima region, 18

  • Novartis Investigative Site

    San Isidro, Lima region, 27

Other trials in Peru

Singapore5 sites

  • Novartis Investigative Site

    Singapore, 119074

  • Novartis Investigative Site

    Singapore, 169609

  • Novartis Investigative Site

    Singapore, 308433

  • Novartis Investigative Site

    Singapore, 529889

  • Novartis Investigative Site

    Singapore, 768828

Other trials in Singapore

Switzerland5 sites

  • Novartis Investigative Site

    Basel, 4031

  • Novartis Investigative Site

    Bern, 3010

  • Novartis Investigative Site

    Biel, 2502

  • Novartis Investigative Site

    Lausanne, 1011

  • Novartis Investigative Site

    Zurich, 8091

Other trials in Switzerland

Croatia4 sites

  • Novartis Investigative Site

    Rijeka, 51000

  • Novartis Investigative Site

    Varaždin, HRV, 42000

  • Novartis Investigative Site

    Zadar, 23000

  • Novartis Investigative Site

    Zagreb, 10000

Other trials in Croatia

Guatemala4 sites

  • Novartis Investigative Site

    Guatemala City, 01010

  • Novartis Investigative Site

    Guatemala City, 01011

  • Novartis Investigative Site

    Guatemala City, 01015

  • Novartis Investigative Site

    Guatemala City, 10110

Other trials in Guatemala

Norway4 sites

  • Novartis Investigative Site

    Loerenskog, NO 1478

  • Novartis Investigative Site

    Oslo, 0450

  • Novartis Investigative Site

    Stavanger, 4068

  • Novartis Investigative Site

    Tromsø, NO-9038

Other trials in Norway

Philippines4 sites

  • Novartis Investigative Site

    Lipa City, Batangas, 4217

  • Novartis Investigative Site

    Quezon City, Manila, 1100

  • Novartis Investigative Site

    Quezon City, 1100

  • Novartis Investigative Site

    Quezon City, 1102

Other trials in Philippines

Serbia4 sites

  • Novartis Investigative Site

    Belgrade, 11000

  • Novartis Investigative Site

    Belgrade, 11040

  • Novartis Investigative Site

    Niš, 18000

  • Novartis Investigative Site

    Niška Banja, 18205

Other trials in Serbia

Finland3 sites

  • Novartis Investigative Site

    Jyväskylä, 40620

  • Novartis Investigative Site

    Oulu, 90220

  • Novartis Investigative Site

    Tampere, 33520

Other trials in Finland

Slovenia2 sites

  • Novartis Investigative Site

    Golnik, 4204

  • Novartis Investigative Site

    Ljubljana, 1000

Other trials in Slovenia

About this study

Official title: A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction (PARAGON-HF)

The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.

Read the detailed description

This was a multicenter, randomized, double-blind, parallel group, active-controlled, study to evaluate the efficacy and safety of sacubitril/valsartan compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. Specifically, the study evaluated the effect of sacubitril/valsartan compared to the active comparator valsartan in the reduction of the rate of CV death and total HF hospitalizations in patients with HFpEF. The trial consisted of two periods: (1) a single-blind treatment run-in epoch that lasted from 3 to 8 weeks, in which patients received valsartan 80 mg bid, followed by sacubitril/valsartan 100 mg bid and (2) a double-blind randomized treatment epoch (sacubitril/valsartan 200 mg bid or valsartan 160 mg bid). In this study, investigators were responsible for assessing and submitting all events which could potentially fulfill the criteria for the primary, secondary, or other clinical endpoints to a Clinical Endpoint Committee (CEC). Investigator reported events were assessed by the CEC for adjudication.

For angioedema or angioedema-like events, investigators completed an Adjudication Questionnaire for an Angioedema-like Event form. All angioedema reports were forwarded to an Angioedema Adjudication Committee (AAC) by Novartis for assessment.

Being tested
LCZ696, Valsartan
Keywords
Heart failure, preserved ejection fraction, diastolic heart failure
Medical subject headings
Heart Failure, Heart Failure, Diastolic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LCZ696Drug

    LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.

  • ValsartanDrug

    Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.

Study groups in NCT01920711
Study groupRoleWhat they receive
LCZ696ExperimentalSingle Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of LCZ696 during the double blind period is 200 mg b.i.d.
Receives: Drug: LCZ696
ValsartanActive comparatorSingle Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of Valsartan during the double blind period is 160 mg b.i.d.
Receives: Drug: Valsartan

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations.

    The primary objective of this study is to compare LCZ696 to valsartan in reducing the rate of the composite endpoint of CV death and total (first and recurrent) HF hospitalizations, in HF patients (New York Heart Association [NYHA] Class II-IV) with preserved ejection fraction (left ventricular ejection fraction [LVEF] ≥45%). The treatment arm with the lower rate of events will be deemed as having a successful response.

    Measured: Total follow up time (up to 57 months)

Secondary outcomes (4)

  1. Change in the Clinical Summary Score From Baseline to Month 8 by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    The KCCQ is a validated instrument for self-assessment of quality of life and health status in heart failure (HF) patients. The clinical summary score, which is derived from the physical limitations and heart failure (HF) symptoms domains of the KCCQ is a valid measure for assessing the patient's health aspects that may be influenced by CV medications. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. Evaluation of change from baseline to month 8 in KCCQ a most sensitive, specific, and responsive health-related quality of life measure for heart failure symptoms and physical limitations.

    Measured: Baseline, 8 months

  2. Change From Baseline to Month 8 in New York Heart Association (NYHA) Functional Class

    Evaluation of change from baseline to Month 8 in NYHA functional class, a well established grading scale used to classify a heart failure's (HF) patients' level of functionality based on the signs and symptoms of HF exhibited by the patient.

    Measured: Baseline, 8 months

  3. Participants With First Occurrence of a Composite Renal Endpoint

    Analyis of composite renal endpoint defined as renal death, or reaching ESRD, or ≥50% decline in eGFR relative to baseline, using Cox's proportional hazards model.

    Measured: Randomization to total follow-up time (up to 57 months)

  4. All-cause Mortality

    Analysis for all-cause mortality using Cox's proportional hazards model.

    Measured: Randomization to total follow up time (up to 57 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2013 (estimated)
  2. Study start18 Jul 2014
  3. Primary completion7 Jun 2019
  4. Study completion7 Jun 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
4,822 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01920711
Sponsor's protocol ID
CLCZ696D2301
Other IDs
2013-001747-31
Acronym
PARAGON-HF
Status last verified
Sep 2020
First submitted
8 Aug 2013
Last updated
29 Sep 2020
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Publications

  • Lu H, Claggett BL, Ostrominski JW, Pfeffer MA, Pitt B, Jhund PS, McMurray JJV, Solomon SD, Desai AS, Vaduganathan M. Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials. Eur J Heart Fail. 2026 Aug 30:xuag245. doi: 10.1093/ejhf/xuag245. Online ahead of print.

    PubMed 42669134

  • Yang M, Henderson AD, Anand IS, Desai AS, Lam CSP, Maggioni AP, Martinez FA, Rouleau JL, Swedberg K, Vaduganathan M, van Veldhuisen DJ, Zannad F, Zile MR, Packer M, Rizkala A, Lewis EF, Jhund PS, Solomon SD, McMurray JJV. Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF. Eur Heart J Cardiovasc Pharmacother. 2025 Nov 4;11(7):574-589. doi: 10.1093/ehjcvp/pvaf064.

    PubMed 40839760

  • Lu H, Claggett BL, Minamisawa M, Ostrominski JW, Foa A, Pabon MA, Kalayci A, Vaduganathan M, Cikes M, Shah AM, Desai AS, McMurray JJV, Jhund PS, Packer M, Lefkowitz M, Rouleau JL, Zile MR, Zannad F, Hegde SM, Solomon SD, Skali H. Prognostic Significance of Nutritional Scores in Patients With Heart Failure: Insights From the PARAGON-HF Trial. J Am Heart Assoc. 2025 May 6;14(9):e038872. doi: 10.1161/JAHA.124.038872. Epub 2025 Apr 23.

    PubMed 40265602

  • Kondo T, Jhund PS, Anand IS, Claggett BL, Desai AS, Docherty KF, Lam CSP, Lefkowitz MP, Maggioni AP, Martinez FA, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Packer M, Solomon SD, McMurray JJV. Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF. JACC Heart Fail. 2025 Jun;13(6):927-939. doi: 10.1016/j.jchf.2024.12.010. Epub 2025 Mar 12.

    PubMed 40088233

  • Peikert A, Vaduganathan M, Claggett BL, Kulac IJ, Litwin S, Zile M, Desai AS, Jhund PS, Butt JH, Lam CSP, Martinez F, Van Veldhuisen DJ, Zannad F, Rouleau J, Lefkowitz M, McMurray JJV, Solomon SD, Packer M. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial. Eur Heart J. 2025 Jul 1;46(25):2372-2390. doi: 10.1093/eurheartj/ehaf057.

    PubMed 39873282

  • Mc Causland FR, Vaduganathan M, Claggett B, Gori M, Jhund PS, McGrath MM, Neuen BL, Packer M, Pfeffer MA, Rouleau JL, Senni M, Swedberg K, Zannad F, Zile M, Lefkowitz MP, McMurray JJV, Solomon SD. Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF Trial. JACC Heart Fail. 2025 Jan;13(1):105-114. doi: 10.1016/j.jchf.2024.08.022. Epub 2024 Nov 20.

    PubMed 39570234

  • Lu H, Claggett BL, Packer M, Pfeffer MA, Swedberg K, Rouleau J, Zile MR, Lefkowitz M, Desai AS, Jhund PS, McMurray JJV, Solomon SD, Vaduganathan M. Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials. Eur J Heart Fail. 2025 Jan;27(1):60-68. doi: 10.1002/ejhf.3487. Epub 2024 Oct 22.

    PubMed 39439294

  • Lu H, Claggett BL, Packer M, Pabon MA, Pfeffer MA, Lewis EF, Lam CSP, Rouleau J, Zile MR, Lefkowitz M, Desai AS, Jhund PS, McMurray JJV, Solomon SD, Vaduganathan M. Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF Trials. JACC Heart Fail. 2025 Jan;13(1):58-71. doi: 10.1016/j.jchf.2024.08.008. Epub 2024 Aug 31.

    PubMed 39387766

  • Lu H, Claggett BL, Packer M, Pfeffer MA, Lam CSP, Zile MR, Desai AS, Jhund P, Lefkowitz M, McMurray JJV, Solomon SD, Vaduganathan M. Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON-HF trial. Eur J Heart Fail. 2025 Jan;27(1):85-95. doi: 10.1002/ejhf.3414. Epub 2024 Sep 1.

    PubMed 39217577

  • Lu H, Chatur S, Lee S, Inciardi RM, Abanda M, Mc Causland FR, Kalayci A, Taheri KK, Shah AM, Cikes M, Claggett BL, Prasad N, Lam CSP, O'Meara E, Wang X, McMurray JJV, Pfeffer MA, Hegde SM, Solomon SD, Skali H. Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial. Circ Heart Fail. 2024 Oct;17(10):e011942. doi: 10.1161/CIRCHEARTFAILURE.124.011942. Epub 2024 Aug 30.

    PubMed 39212045

  • Lu H, Claggett BL, Packer M, Lam CSP, Swedberg K, Rouleau J, Zile MR, Lefkowitz M, Desai AS, Jhund P, McMurray JJV, Solomon SD, Vaduganathan M. Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials. JAMA Cardiol. 2024 Nov 1;9(11):1047-1052. doi: 10.1001/jamacardio.2024.2566.

    PubMed 39210725

  • Yoon M, Kim W, Kook W, Park JJ, Greenberg B. Analysis of the PARAGON-HF Study Results Using Win Ratio. Circ Heart Fail. 2024 Sep;17(9):e011860. doi: 10.1161/CIRCHEARTFAILURE.124.011860. Epub 2024 Aug 28.

    PubMed 39193709

  • Lassen MCH, Ostrominski JW, Claggett BL, Packer M, Zile M, Desai AS, Shah AM, Cikes M, Merkely B, Gori M, Wang X, Hegde SM, Pfeffer MA, Lefkowitz M, McMurray JJV, Solomon SD, Vaduganathan M. Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF. Eur J Heart Fail. 2024 Aug;26(8):1762-1774. doi: 10.1002/ejhf.3304. Epub 2024 Jun 26.

    PubMed 38932589

  • Patel-Murray NL, Zhang L, Claggett BL, Xu D, Serrano-Fernandez P, Healey M, Wandel S, Chen CW, Jacob J, Xu H, Turner GM, Chutkow W, Yates DP, O'Donnell CJ, Prescott MF, Lefkowitz M, Gimpelewicz CR, Beste MT, Zhao F, Gou L, Desai AS, Jhund PS, Packer M, Pfeffer MA, Redfield MM, Rouleau JL, Zannad F, Zile MR, McMurray JJV, Mendelson MM, Solomon SD, Cunningham JW. Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy. J Am Heart Assoc. 2024 Jul 2;13(13):e033544. doi: 10.1161/JAHA.123.033544. Epub 2024 Jun 21.

    PubMed 38904251

  • Chatur S, Beldhuis IE, Claggett BL, McCausland FR, Neuen BL, Desai AS, Rouleau JL, Zile MR, Packer M, Pfeffer MA, Lefkowitz MP, McMurray JJV, Solomon SD, Vaduganathan M. Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2. JACC Heart Fail. 2024 Oct;12(10):1692-1703. doi: 10.1016/j.jchf.2024.03.014. Epub 2024 Jun 5.

    PubMed 38842957

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing LCZ696 and Valsartan in people with Heart Failure With Preserved Ejection Fraction, run by Novartis Pharmaceuticals at 715 sites in 43 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 715 sites in United States, Germany, China, Spain, United Kingdom and 38 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Sep 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. (time frame: Total follow up time (up to 57 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01920711, which also lists 56 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2020.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in